CW
BMRN icon

Connectus Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Connectus Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$263K Hold
3,011
– – 0.01% 336
2023
Q4 		$290K Hold
3,011
– – 0.01% 457
2023
Q3 		$266K Hold
3,011
– – 0.01% 443
2023
Q2 		$261K Buy
+3,011
New +$283K 0.01% 415

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Connectus Wealth's BMRN Position: Q1 2024 in Review

Connectus Wealth held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2024 at 3,011 shares worth $263K. The position accounts for 0.01% of the portfolio, ranked #336.

Connectus Wealth first reported a position in BMRN in Q2 2023 and has held it in 4 quarters since. The position peaked at $290K in Q4 2023. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Connectus Wealth held 3,011 shares of BioMarin Pharmaceuticals worth $263K as of Q1 2024.
  • Connectus Wealth left its BioMarin Pharmaceuticals share count unchanged in Q1 2024.
  • BioMarin Pharmaceuticals made up 0.01% of Connectus Wealth's portfolio in Q1 2024, its #336 holding.
  • Connectus Wealth first reported a position in BioMarin Pharmaceuticals in Q2 2023 and has held it in 4 quarters since.
  • Connectus Wealth's BioMarin Pharmaceuticals position peaked at $290K in Q4 2023.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Connectus Wealth's 13F filing for Q1 2024, filed 14 May 2024.